Lisata Therapeutics, Inc. Sustainability Profile
Lisata Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, is at the forefront of developing innovative therapies for serious diseases. Founded in 2020, Lisata focuses on advancing its proprietary platform to create targeted treatments that address unmet medical needs, particularly in oncology and autoimmune disorders. With a commitment to scientific excellence, Lisata Therapeutics has achieved significant milestones, including the progression of its lead product candidates through various stages of clinical development. The company’s unique approach combines cutting-edge technology with a deep understanding of disease mechanisms, setting it apart in the competitive biopharmaceutical landscape. As it continues to expand its operational reach, Lisata is poised to make a substantial impact on patient care and therapeutic options in the industry.
DitchCarbon Score
How does Lisata Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lisata Therapeutics, Inc.'s score of 25 is lower than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Lisata Therapeutics, Inc.'s reported carbon emissions
In 2022, Lisata Therapeutics, Inc. reported total carbon emissions of approximately 686,600 kg CO2e, comprising 404,000 kg CO2e from Scope 1 emissions and 282,600 kg CO2e from Scope 2 emissions. This data reflects a significant reduction from 2021, where Scope 1 emissions alone were reported at 533,000,000 kg CO2e. Despite these figures, Lisata Therapeutics has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi). The company does not appear to have cascaded emissions data from a parent organisation, indicating that their reported figures are solely their own. Lisata Therapeutics is committed to addressing climate change, although specific climate pledges or reduction initiatives have not been detailed. The company’s emissions data highlights their ongoing efforts to monitor and manage their carbon footprint as part of their broader environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 533,000,000 | 000,000 |
| Scope 2 | - | 000,000 |
| Scope 3 | - | - |
How Carbon Intensive is Lisata Therapeutics, Inc.'s Industry?
How Carbon Intensive is Lisata Therapeutics, Inc.'s Location?
Lisata Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Lisata Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
